PBA
PCVX icon

Paradigm Biocapital Advisors’s Vaxcyte PCVX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-276,800
Closed -$31.6M – 37
2024
Q3 		$31.6M Buy
+276,800
New +$24.9M 1.07% 28

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Paradigm Biocapital Advisors's PCVX Position: Q2 2026 in Review

Paradigm Biocapital Advisors reduced its Vaxcyte (PCVX) stake by 56% in Q2 2026, selling an estimated $145M and leaving 2,127,852 shares worth $124M. The position accounts for 2.32% of the portfolio, ranked #15.

Paradigm Biocapital Advisors first reported a position in PCVX in Q1 2024 and has held it in 10 quarters since. The position peaked at $279M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Paradigm Biocapital Advisors held 2,127,852 shares of Vaxcyte worth $124M as of Q2 2026.
  • Paradigm Biocapital Advisors sold 2,665,168 Vaxcyte shares in Q2 2026, an estimated $145M.
  • Vaxcyte made up 2.32% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #15 holding.
  • Paradigm Biocapital Advisors first reported a position in Vaxcyte in Q1 2024 and has held it in 10 quarters since.
  • Paradigm Biocapital Advisors's Vaxcyte position peaked at $279M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.